Jackson Square Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Jackson Square Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,750	Closed	-$4K	–	357
2020 Q3	$4K	Hold	1,750	–	–	﹤0.01%	310
2020 Q2	$6K	Hold	1,750	–	–	﹤0.01%	281
2020 Q1	$7K	Hold	1,750	–	–	0.01%	247
2019 Q4	$5K	Buy	+1,750	New	+$4.55K	﹤0.01%	316

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jackson Square Capital's BMY.RT Position: Q4 2020 in Review

Jackson Square Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 1,750 shares — an estimated $4K sold.

Jackson Square Capital first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $7K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Jackson Square Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Jackson Square Capital sold 1,750 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $4K.
Jackson Square Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Jackson Square Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $7K in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Jackson Square Capital's 13F filing for Q4 2020, filed 5 Mar 2021.